Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging

Particle and Fibre Toxicology

Volumn 7, Issue , 2010, Pages

  Bhaskar, Sonu ^a,b   Tian, Furong ^c   Stoeger, Tobias ^c   Kreyling, Wolfgang ^c   de la Fuente, Jesús M ^a   Grazú, Valeria ^a   Borm, Paul ^d   Estrada, Giovani ^c   Ntziachristos, Vasilis ^e   Razansky, Daniel ^e  

^a Instituto de Nanociencia y Materiales de Aragón   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d ZUYD UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DELAVIRDINE; DIMINAZENE; DOXORUBICIN; GADOLINIUM; GEMCITABINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LOPERAMIDE; METHACRYLIC ACID METHYL ESTER; METHAMPHETAMINE; MORPHINE; MRZ 2 576; NANOCARRIER; NANOPARTICLE; NERAMEXANE; PACLITAXEL; PARVOVIRUS VECTOR; POLOXAMER; POLYENBUCRILATE; POLYGLACTIN; POLYMER; POLYSORBATE 80; RIVASTIGMINE; SAQUINAVIR; STAVUDINE; SUPERPARAMAGNETIC IRON OXIDE; SURFACTANT; TACRINE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CENTRAL NERVOUS SYSTEM AGENTS; DIAGNOSTIC AGENT; DRUG CARRIER;

AFRICAN TRYPANOSOMIASIS; BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD BRAIN BARRIER; BRAIN MICROCIRCULATION; BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED DRUG RELEASE; DIAGNOSTIC VALUE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; GLIOMA; HUMAN; MEMBRANE TRANSPORT; MOLECULAR IMAGING; NANOMEDICINE; NANOPHARMACEUTICS; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD INJURY; TIGHT JUNCTION; ANIMAL; BRAIN; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NANOMEDICINE; NANOPARTICLES;

EID: 77951246386     PISSN: 17438977     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8977-7-3     Document Type: Review

References (230)

1. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor Nanocrystals as Fluorescent Biological Labels. Science 1998, 281(5385):2013-2016. 10.1126/science.281.5385.2013, 9748157.
2. Chan WC, Nie S. Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection. Science 1998, 281(5385):2016-2018. 10.1126/science.281.5385.2016, 9748158.
3. Tian F, Prina-Mello A, Estrada G, Beyerle A, Moeller W, Schulz H, Kreyling W, Stoeger T. A novel assay for the quantification of internalized nanoparticles in macrophages. Nanotoxicology 2008, 2(4):232-242.
4. Cui D, Tian F, Coyer S, Wang J, Pan B, Gao F, He R, Zhang Y. Effects of Antisense-myc-conjugated Single-Walled Carbon Nanotubes on HL-60 cells. Journal of Nanoscience and Nanotechnology 2007, 7:1639-1641. 10.1166/jnn.2007.348, 17450937.
5. Pantarotto D, Partidos CD, Hoebeke J, Brown F, Kramer E, Briand J-P, Muller S, Prato M, Bianco A. Immunization with Peptide-Functionalized Carbon Nanotubes Enhances Virus-Specific Neutralizing Antibody Responses. Chemistry & Biology 2003, 10(10):961-966.
6. Edelstein RL, Tamanaha CR, Sheehan PE, Miller MM, Baselt DR, Whitman LJ, Colton RJ. The BARC biosensor applied to the detection of biological warfare agents. Biosensors and Bioelectronics 2000, 14(10-11):805-813. 10.1016/S0956-5663(99)00054-8, 10945455.
7. Nam J-M, Thaxton CS, Mirkin CA. Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins. Science 2003, 301(5641):1884-1886. 10.1126/science.1088755, 14512622.
8. Cui D, Tian F, Kong Y, Ozkan C, Titushikin I, Gao H. Effects of single-walled carbon nanotubes on the polymerase chain reaction. Nanotechnology 2004, 15(1):154-157.
9. de la Isla A, Brostow W, Bujard B, Estevez M, Rodriguez JR, Vargas S, Castaño VM. Nanohybrid scratch resistant coatings for teeth and bone viscoelasticity manifested in tribology. Materials Research Innovations 2003, 7(2):110-114.
10. Ma J, Huifen W, Kong LB, Peng KW. Biomimetic processing of nanocrystallite bioactive apatite coating on titanium. Nanotechnology 2003, 14:619-623.
11. Shinkai M, Yanase M, Suzuki M, Hiroyuki H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes. Journal of Magnetism and Magnetic Materials 1999, 194(1-3):176-184.
12. Molday RS, Mackenzie D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. Journal of Immunological Methods 1982, 52(3):353-367. 10.1016/0022-1759(82)90007-2, 7130710.
13. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990, 175(2):489-493.
14. Parak W, Boudreau R, Gros ML, Gerion D, Zanchet D, Micheel C, Williams S, Alivisatos AP, Larabell C. Cell Motility and Metastatic Potential Studies Based on Quantum Dot Imaging of Phagokinetic Tracks. Advanced Materials 2002, 14(12):882-885.
15. Czerniawska A. Experimental investigations on the penetration of 198Au from nasal mucous membrane into cerebrospinal fluid. Acta Otolaryngol 1970, 70(1):58-61.
16. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, et al. Strategies to advance translational research into brain barriers. The Lancet Neurology 2008, 7(1):84-96.
17. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated?. Drug Discovery Today 2002, 7(1):5-7. 10.1016/S1359-6446(01)02082-7, 11790589.
18. Bradbury M, Begley DJ, Kreuter J, . (Eds) The Blood-Brain Barrier and Drug Delivery to the CNS. 2000, Informa Healthcare, USA, (Eds).
19. Ghose AK, Viswanadhan VN, Wendoloski JJ. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases. Journal of Combinatorial Chemistry 1999, 1(1):55-68. 10.1021/cc9800071, 10746014.
20. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 2000, 44(1):235-249. 10.1016/S1056-8719(00)00107-6, 11274893.
21. Taggart DP, Choudhary B, Anastasiadis K, Abu-Omar Y, Balacumaraswami L, Pigott DW. Preliminary experience with a novel intraoperative fluorescence imaging technique to evaluate the patency of bypass grafts in total arterial revascularization. The Annals of Thoracic Surgery 2003, 75(3):870-873. 10.1016/S0003-4975(02)04669-6, 12645709.
22. Chen J, Tung C-H, Allport JR, Chen S, Weissleder R, Huang PL. Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity After Myocardial Infarction. Circulation 2005, 111(14):1800-1805. 10.1161/01.CIR.0000160936.91849.9F, 15809374.
23. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Fred GD, Grazette RL, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magnetic Resonance in Medicine 2005, 54(3):718-724. 10.1002/mrm.20617, 16086367.
24. Ntziachristos V, Tung C-H, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002, 8(7):757-761. 10.1038/nm729, 12091907.
25. Razansky D, Distel M, Vinegoni C, Ma R, Perrimon N, Koster RW, Ntziachristos V. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nature Photonics 2009, 3:412-417.
26. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology & Therapeutics 2004, 104(1):29-45.
27. Chen Y, Dalwadi G, Benson HAE. Drug Delivery Across the Blood-Brain Barrier. Current Drug Delivery 2004, 1:361-376. 10.2174/1567201043334542, 16305398.
28. Olivier J-C. Drug Transport to Brain with Targeted Nanoparticles. NeuroRX 2005, 2(1):108-119. 10.1602/neurorx.2.1.108, 539329, 15717062.
29. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?. Drug Discovery Today 2008, 13(23-24):1099-1106. 10.1016/j.drudis.2008.09.005, 18848640.
30. Persidsky Y, Ramirez S, Haorah J, Kanmogne G. Blood-brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions. Journal of Neuroimmune Pharmacology 2006, 1(3):223-236. 10.1007/s11481-006-9025-3, 18040800.
31. Hawkins BT, Davis TP. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease. Pharmacol Rev 2005, 57(2):173-185. 10.1124/pr.57.2.4, 15914466.
32. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969, 40(3):648-677. 10.1083/jcb.40.3.648, 2107650, 5765759.
33. Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM. Barriers in the brain: a renaissance?. Trends in Neurosciences 2008, 31(6):279-286. 10.1016/j.tins.2008.03.003, 18471905.
34. Saunders N, Knott G, Dziegielewska K. Barriers in the Immature Brain. Cellular and Molecular Neurobiology 2000, 20(1):29-40. 10.1023/A:1006991809927, 10690500.
35. Saunders N, Habgood MD, Dziegielewska K. Barrier mechanisms in the brain, II. Immature brain. Clinical and Experimental Pharmacology and Physiology 1999, 26(2):85-91. 10.1046/j.1440-1681.1999.02987.x, 10065326.
36. Saunders N, Habgood MD, Dziegielewska K. Barrier mechanisms in the brain, I. Adult brain. Clinical and Experimental Pharmacology and Physiology 1999, 26(1):11-19. 10.1046/j.1440-1681.1999.02986.x, 10027064.
37. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967, 34(1):207-217. 10.1083/jcb.34.1.207, 2107213, 6033532.
38. Stewart PA. Endothelial Vesicles in the Blood-Brain Barrier: Are They Related to Permeability?. Cellular and Molecular Neurobiology 2000, 20(2):149-163. 10.1023/A:1007026504843, 10696507.
39. Decleves X, Amiel A, Delattre J-Y, Scherrmann J-M. Role of ABC Transporters in the Chemoresistance of Human Gliomas. Current Cancer Drug Targets 2006, 6:433-445. 10.2174/156800906777723930, 16918310.
40. Burkhard S, Heiko S. The Blood-brain Barrier and the Outer Blood-retina Barrier. Medicinal Chemistry Reviews - Online 2005, 2:11-26.
41. Spector R. Thymidine transport and metabolism in choroid plexus: effect of diazepam and thiopental. J Pharmacol Exp Ther 1985, 235(1):16-19.
42. Begley D, Brightman M. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003, 61:39-78.
43. Zeuthen T. Secondary active transport of water across ventricular cell membrane of choroid plexus epithelium of Necturus maculosus. J Physiol 1991, 444(1):153-173. 1179926, 1822549.
44. Taylor EM. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders. Clinical Pharmacokinetics 2002, 41:81-92. 10.2165/00003088-200241020-00001, 11888329.
45. Kabanov AV, Batrakova EV, Miller DW. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Advanced Drug Delivery Reviews 2003, 55(1):151-164. 10.1016/S0169-409X(02)00176-X, 12535579.
46. Graff CL, Pollack GM. Drug Transport at the Blood-Brain Barrier and the Choroid Plexus. Current Drug Metabolism 2004, 5:95-108. 10.2174/1389200043489126, 14965253.
47. Tsuji A. Small Molecular Drug Transfer across the Blood-Brain Barrier via Carrier-Mediated Transport Systems. NeuroRX 2005, 2(1):54-62. 10.1602/neurorx.2.1.54, 539320, 15717057.
48. Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M. Involvement of organic anion transporters in the efflux of uremic toxins across the bloodbrain barrier. Journal of Neurochemistry 2006, 96:1051-1059. 10.1111/j.1471-4159.2005.03550.x, 16445853.
49. Sun JJ, Xie L, Liu XD. Transport of carbamazepine and drug interactions at blood-brain barrier. Acta Pharmacologica Sinica 2006, 27:249-253. 10.1111/j.1745-7254.2006.00246.x, 16412277.
50. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic Anion-Transporting Polypeptides Mediate Transport of Opioid Peptides across Blood-Brain Barrier. J Pharmacol Exp Ther 2000, 294(1):73-79.
51. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70(3):735-740. 10.1016/j.ejpb.2008.07.005, 18684400.
52. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology 2005, 76(1):22-76. 10.1016/j.pneurobio.2005.04.006, 16011870.
53. Löscher W, Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family. NeuroRX 2005, 2(1):86-98. 10.1602/neurorx.2.1.86, 539326, 15717060.
54. Fischer H, Gottschlich R, Seelig A. Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion. Journal of Membrane Biology 1998, 165(3):201-211. 10.1007/s002329900434, 9767674.
55. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. Journal of Neural Transmission 2006, 113(4):477-485. 10.1007/s00702-005-0409-y, 16550326.
56. Ikumi Tamai AT. Transporter-mediated permeation of drugs across the blood-brain barrier. Journal of Pharmaceutical Sciences 2000, 89(11):1371-1388. 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D, 11015683.
57. Banks WA, Kastin AJ, Ehrensing CA. Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. Journal of Neuroscience Research 1993, 35(6):690-695. 10.1002/jnr.490350611, 8105102.
58. Maratos-Flier E, Kao CY, Verdin EM, King GL. Receptor-mediated vectorial transcytosis of epidermal growth factor by Madin-Darby canine kidney cells. J Cell Biol 1987, 105(4):1595-1601. 10.1083/jcb.105.4.1595, 2114648, 3312235.
59. King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science 1985, 227(4694):1583-1586. 10.1126/science.3883490, 3883490.
60. Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993, 104(2):521-532.
61. Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. Journal of Biological Chemistry 1987, 262(31):15214-15219.
62. Sai Y, Kajita M, Tamai I, Wakama J, Wakamiya T, Tsuji A. Adsorptive-mediated endocytosis of a basic peptide in enterocyte-like Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 1998, 275(3):G514-520.
63. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, Qi M, Toh J, Xu G, Prasad PN, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Research 2008, 1203:133-148. 10.1016/j.brainres.2008.01.093, 2826119, 18329007.
64. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Fernandez S, Chawda R, Shanahan T, Schwartz S. Tight Junction Regulation by Morphine and HIV-1 Tat Modulates Blood-Brain Barrier Permeability. Journal of Clinical Immunology 2008, 28(5):528-541. 10.1007/s10875-008-9208-1, 18574677.
65. Choi JJ, Pernot M, Brown TR, et al. Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. Phys Med Biol 2007, 52(18):5509-5530. 10.1088/0031-9155/52/18/004, 17804879.
66. Béduneau A, Saulnier P, Benoit J-P. Active targeting of brain tumours using nanocarriers. Biomaterials 2007, 28(33):4947-4967. 10.1016/j.biomaterials.2007.06.011, 17716726.
67. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Advanced Drug Delivery Reviews 2007, 59(8):748-758. 10.1016/j.addr.2007.06.008, 2000329, 17659804.
68. Roberts RL, Fine RE, Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993, 104(2):521-532.
69. Witt KA, Huber JD, Egleton RD, Davis TP. Insulin Enhancement of Opioid Peptide Transport across the Blood-Brain Barrier and Assessment of Analgesic Effect. J Pharmacol Exp Ther 2000, 295(3):972-978.
70. Tabernero A, Velasco A, Granda B, Lavado EM, Medina JM. Transcytosis of Albumin in Astrocytes Activates the Sterol Regulatory Element-binding Protein-1, Which Promotes the Synthesis of the Neurotrophic Factor Oleic Acid. J Biol Chem 2002, 277(6):4240-4246. 10.1074/jbc.M108760200, 11724788.
71. Fiori A, Cardelli P, Negri L, Savi MR, Strom R, Erspamer V. Deltorphin transport across the blood brain barrier. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(17):9469-9474. 10.1073/pnas.94.17.9469, 23226, 9256506.
72. Thomas SA, Abbruscato TJ, Hau VS, Gillespie TJ, Zsigo J, Hruby VJ, Davis TP. Structure-Activity Relationships of a Series of [D-Ala2]Deltorphin I and II Analogues; in vitro Blood-Brain Barrier Permeability and Stability. J Pharmacol Exp Ther 1997, 281(2):817-825.
73. Liu H-M, Liu X-F, Yao J-L, Wang C-L, Yu Y, Wang R. Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1. J Pharmacol Exp Ther 2006, 319(1):308-316. 10.1124/jpet.106.106484, 16803861.
74. Dollinger S, Lober S, Klingenstein R, Korth C, Gmeiner P. A Chimeric Ligand Approach Leading to Potent Antiprion Active Acridine Derivatives: Design, Synthesis, and Biological Investigations. Journal of Medicinal Chemistry 2006, 49(22):6591-6595. 10.1021/jm060773j, 17064077.
75. You JO, Auguste DT. Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. Biomaterials 2008, 29(12):1950-1957. 10.1016/j.biomaterials.2007.12.041, 18255142.
76. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Advanced Drug Delivery Reviews 2007, 59(6):454-477. 10.1016/j.addr.2007.04.011, 17570559.
77. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier. Journal of Drug Targeting 2002, 10:317-325. 10.1080/10611860290031877, 12164380.
78. Kreuter J. Influence of the Surface Properties on Nanoparticle-Mediated Transport of Drugs to the Brain. Journal of Nanoscience and Nanotechnology 2004, 4:484-488. 10.1166/jnn.2003.077, 15503433.
79. Liu G, Men P, Harris PLR, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neuroscience Letters 2006, 406(3):189-193. 10.1016/j.neulet.2006.07.020, 16919875.
80. Kim H, Gil S, Andrieux K, Nicolas V, Appel M, Chacun H, le Desma D, Taran F, Georgin D, et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cellular and Molecular Life Sciences CMLS 2007, 64:356-364. 10.1007/s00018-007-6390-x, 17256088.
81. Hammer A, Malle E, Zimmer A, et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. Journal of Controlled Release 2007, 117(3):301-311. 10.1016/j.jconrel.2006.11.020, 17239472.
82. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. Journal of Controlled Release 2007, 117(1):51-58. 10.1016/j.jconrel.2006.10.015, 17150277.
83. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. Journal of Controlled Release 2007, 118(1):54-58. 10.1016/j.jconrel.2006.12.012, 17250920.
84. Demeule M, Currie J-C, Bertrand Y, Christian C, Nguyen T, gina A, Gabathuler R, Castaigne J-P, liveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. Journal of Neurochemistry 2008, 106:1534-1544. 10.1111/j.1471-4159.2008.05492.x, 18489712.
85. Sakaguchi M, Yagi Y, Seno M, et al. Intracellular Delivery of Glutathione S-transferase-fused Proteins into Mammalian Cells by Polyethylenimine-Glutathione Conjugates. J Biochem 2008, 144(4):447-455. 10.1093/jb/mvn087, 18603589.
86. Lu W, Sun Q, Wan J, She Z, Jiang X-G. Cationic Albumin-Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumours via Intravenous Administration. Cancer Res 2006, 66(24):11878-11887. 10.1158/0008-5472.CAN-06-2354, 17178885.
87. dos Santos W, Rahman J, Klein N, Male D. Distribution and analysis of surface charge on brain endothelium in vitro and in situ. Acta Neuropathologica 1995, 90(3):305-311. 10.1007/BF00296515, 8525805.
88. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, Golomb G. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. Journal of Controlled Release 2008, 132(2):84-90. 10.1016/j.jconrel.2008.08.017, 18805446.
89. Singh R, James W, Lillard J. Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology 2009, 86(1):215-223. 10.1016/j.yexmp.2008.12.004, 19186176.
90. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier. Drug Development and Industrial Pharmacy 2002, 28(1):1-13. 10.1081/DDC-120001481, 11858519.
91. Mortensen LJ, Oberdörster G, Pentland AP, DeLouise LA. In vivo Skin Penetration of Quantum Dot Nanoparticles in the Murine Model: The Effect of UVR. Nano Letters 2008, 8(9):2779-2787. 10.1021/nl801323y, 18687009.
92. Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine 2008, 3:357-365. 10.2217/17435889.3.3.357, 18510430.
93. de la Fuente JM, Berry CC. Tat Peptide as an Efficient Molecule To Translocate Gold Nanoparticles into the Cell Nucleus. Bioconjugate Chemistry 2005, 16(5):1176-1180. 10.1021/bc050033+, 16173795.
94. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008, 29(33):4429-4438. 10.1016/j.biomaterials.2008.08.004, 2570783, 18760470.
95. Scherrmann J-M, Temsamani J. The use of Pep: Trans vectors for the delivery of drugs into the central nervous system. International Congress Series 2005, 1277:199-211.
96. Hu Q, Chen C, Yan J, Yang X, Shi X, Zhao J, Lei J, Yang L, Wang K, Chen L, et al. Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol 2009, 216(1):35-46. 10.1016/j.expneurol.2008.11.007, 19073180.
97. Gonzalez-Alegre P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacology & Therapeutics 2007, 114(1):34-55.
98. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 2007, 59(2-3):141-152. 10.1016/j.addr.2007.03.008, 17434235.
99. Hoyer D, Dev KK. RNA interference as a therapeutic strategy for treating CNS disorders. Drug Discovery Today: Therapeutic Strategies 2006, 3(4):451-456.
100. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discovery Today 2006, 11(1-2):67-73. 10.1016/S1359-6446(05)03668-8, 16478693.
101. Leung RKM, Whittaker PA. RNA interference: From gene silencing to gene-specific therapeutics. Pharmacology & Therapeutics 2005, 107(2):222-239.
102. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006, 5(9):741-754. 10.1038/nrd2110, 16915232.
103. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. Journal of Controlled Release 2009, 134(1):55-61. 10.1016/j.jconrel.2008.10.016, 19038299.
104. Ikeda E, Takubo K, Kodama T, Okada Y. Brain-Specific Expression of Vascular Endothelial Growth Factor 146 Correlates with the Blood-Brain Barrier Induction in Quail Embryos. Developmental Neuroscience 2008, 30(5):331-339. 10.1159/000142734, 18594132.
105. Deguchi Y, Okutsu H, Okura T, Yamada S, Kimura R, Yuge T, Furukawa A, Morimoto K, Tachikawa M, Ohtsuki S, et al. Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. Journal of Neurochemistry 2002, 83(2):381-389. 10.1046/j.1471-4159.2002.01129.x, 12423248.
106. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994, 135(5):1753-1761. 10.1210/en.135.5.1753, 7525251.
107. Townsend SA, Evrony GD, Gu FX, Schulz MP, Brown RH, Langer R. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007, 28(34):5176-5184. 10.1016/j.biomaterials.2007.08.011, 2435502, 17854886.
108. Pardridge WM, Triguero D, Buciak J, Yang J. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J Pharmacol Exp Ther 1990, 255(2):893-899.
109. Lu W, Zhang Y, Tan Y-Z, Hu K-L, Jiang X-G, Fu S-K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. Journal of Controlled Release 2005, 107(3):428-448. 10.1016/j.jconrel.2005.03.027, 16176844.
110. Lu W, Tan Y-Z, Hu K-L, Jiang X-G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. International Journal of Pharmaceutics 2005, 295(1-2):247-260. 10.1016/j.ijpharm.2005.01.043, 15848009.
111. Pan W, Barron M, Hsuchou H, Tu H, Kastin AJ. Increased Leptin Permeation across the Blood-Brain Barrier after Chronic Alcohol Ingestion. Neuropsychopharmacology 2007, 33(4):859-866. 10.1038/sj.npp.1301452, 17487223.
112. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity: relationship to plasma levels and adiposity in humans. Peptides 1999, 20:1341-1345. 10.1016/S0196-9781(99)00139-4, 10612449.
113. Fillebeen C, Descamps L, Dehouck M-P, Fenart L, Benaissa M, Spik G, Cecchelli R, Pierce A. Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier. J Biol Chem 1999, 274(11):7011-7017. 10.1074/jbc.274.11.7011, 10066755.
114. Karkan D, Pfeifer C, Vitalis TZ, Arthur G, Ujiie M, Chen Q, Tsai S, Koliatis G, Gabathuler R, Jefferies WA. A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier. PLoS ONE 2008, 3(6):2469.
115. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). European Journal of Pharmaceutics and Biopharmaceutics 2009, 71(2):251-256. 10.1016/j.ejpb.2008.08.021, 18805484.
116. Lumenta DB, Plesnila N, Kläsner B, Baethmann A, Pruneau D, Schmid-Elsaesser R, Zausinger S. Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia. Brain Research 2006, 1069(1):227-234. 10.1016/j.brainres.2005.11.043, 16378603.
117. Shir A, Ogris M, Wagner E, Levitzki A. EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcin-oma Tumours in Mice. PLoS Med 2006, 3:125-136.
118. Ay I, Francis JW, Brown RH. VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Research 2008, 1234:198-205. 10.1016/j.brainres.2008.07.121, 18725212.
119. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. European Journal of Clinical Investigation 2006, 36(7):447-58. 10.1111/j.1365-2362.2006.01657.x, 16796601.
120. Khan NA, Di Cello F, Stins M, Kim KS. Gp120-mediated cytotoxicity of human brain microvascular endothelial cells is dependent on p38 mitogen-activated protein kinase activation. Jounral for Neurovirology 2007, 13(3):242-51.
121. Annunziata P. Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. Journal of Neurology 2003, 250(8):901-906. 10.1007/s00415-003-1159-0, 12928906.
122. Prato FS, Wills JM, Roger J, Frappier H, Drost DJ, Lee TY, Shivers RR, Zabel P. Blood-brain barrier permeability in rats is altered by exposure to magnetic fields associated with magnetic resonance imaging at 1.5 T. Microscopical Research and Technology 1994, 27(6):528-534.
123. McKay JC, Prato FS, Thomas AW. A literature review: the effects of magnetic field exposure on blood flow and blood vessels in the microvasculature. Bioelectromagnetics 2007, 28(2):81-98. 10.1002/bem.20284, 17004242.
124. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008, 7(3):243-253. 10.2174/187152708784936608, 2562687, 18673209.
125. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. The Journal of Pharmacology Experimental Therapeutic 1998, 285(3):1260-1265.
126. Baba T, Black KL, Ikezaki K, Chen KN, Becker DP. Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats. Cerebral Blood Flow & Metabolism 1991, 11(4):638-643.
127. Ivey NS, Martin EN, Scheld WM, Nathan BR. A new method for measuring blood-brain barrier permeability demonstrated with Europium-bound albumin during experimental lipopolysaccharide (LPS) induced meningitis in the rat. J Neurosci Methods 2005, 142(1):91-95. 10.1016/j.jneumeth.2004.07.015, 15652621.
128. Nonaka N, Hileman SM, Shioda S, Vo TQ, Banks WA. Effects of lipopolysaccharide on leptin transport across the blood-brain barrier. Brain Research 2004, 1016(1):58-65. 10.1016/j.brainres.2004.04.066, 15234252.
129. Batrakova EV, Zhang Y, Li Y, Li S, Vinogradov SV, Persidsky Y, Alakhov VY, Miller DW, Kabanov AV. Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier. Pharmacology Research 2004, 21(11):1993-2000.
130. Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, Ohno N, Nakashima T. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacology Toxicology 2003, 92(1):21-6. 10.1034/j.1600-0773.2003.920104.x, 12710593.
131. An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008, 112(7):2787-2794. 10.1182/blood-2008-02-141630, 2556614, 18628488.
132. Lu C, Pelech S, Zhang H, Bond J, Spach K, Noubade R, Blankenhorn EP, Teuscher C. Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. Journal of Neuroscience Research 2008, 86(12):2624-2640. 10.1002/jnr.21716, 18500752.
133. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Research 1995, 674(1):171-174. 10.1016/0006-8993(95)00023-J, 7773690.
134. Schroeder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Research 1996, 710(1-2):121-124. 10.1016/0006-8993(95)01375-X, 8963650.
135. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood-Brain Barrier. Peptides 1998, 19(4):777-780. 10.1016/S0196-9781(97)00474-9, 9622035.
136. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. Journal of Controlled Release 1997, 49(1):81-87.
137. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews 2001, 47(1):65-81. 10.1016/S0169-409X(00)00122-8, 11251246.
138. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. International Congress Series 2005, 1277:85-94.
139. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicology Letters 2002, 126(2):131-141. 10.1016/S0378-4274(01)00456-8, 11751017.
140. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. European Journal of Pharmaceutics and Biopharmaceutics 2000, 49(2):103-109. 10.1016/S0939-6411(99)00073-9, 10704892.
141. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998, 87(11):1305-7. 10.1021/js980084y, 9811481.
142. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption topolysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brainperfusion study. J Microencapsul 1998, 15(1):67-74. 10.3109/02652049809006836, 9463808.
143. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J-P, Williams A, Andreux JP, Dormont D, Couvreur P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. Journal of Neuroscience Methods 2001, 111(2):151-155. 10.1016/S0165-0270(01)00450-2, 11595281.
144. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70(1):75-84. 10.1016/j.ejpb.2008.03.009, 18472255.
145. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Research 2008, 1200:159-168. 10.1016/j.brainres.2008.01.039, 18291351.
146. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicology Letters 2008, 178(1):9-19. 10.1016/j.toxlet.2008.01.020, 18374523.
147. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. Journal of Pharmaceutical Sciences 1982, 71(7):790-792. 10.1002/jps.2600710717, 7120064.
148. Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL, Chen ZL. Antitumour effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumour model. Brain Research 2009, 1261(19):91-99. 10.1016/j.brainres.2009.01.011, 19401168.
149. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. European Journal of Pharmaceutics and Biopharmaceutics 2009, 71(2):161-172. 10.1016/j.ejpb.2008.09.003, 18824097.
150. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug Delivery Reviews 2004, 56(9):1257-1272. 10.1016/j.addr.2003.12.002, 15109768.
151. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews 2007, 59(6):491-504. 10.1016/j.addr.2007.04.008, 17532091.
152. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Advanced Drug Delivery Reviews 2007, 59(6):505-521. 10.1016/j.addr.2007.04.009, 17574295.
153. Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate. Journal of Drug Targeting 2002, 10:387-396. 10.1080/1061186021000001832, 12442809.
154. Wang J-X, Sun X, Zhang Z-R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2002, 54(3):285-290. 10.1016/S0939-6411(02)00083-8, 12445558.
155. Kuo Y-C, Su F-L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. International Journal of Pharmaceutics 2007, 340(1-2):143-152. 10.1016/j.ijpharm.2007.03.012, 17418986.
156. Rae CS, Wei Khor I, Wang Q, Destito G, Gonzalez MJ, Singh P, Thomas DM, Estrada MN, Powell E, Finn MG, et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 2005, 343(2):224-235. 10.1016/j.virol.2005.08.017, 16185741.
157. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J, Oberdörster G. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006, 114(8):1172-1178. 1552007, 16882521.
158. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, Schmid G, Brandau W. Biodistribution of 1.4- and 18-nm Gold Particles in Rats. Small 2008, 4(12):2108-2111. 10.1002/smll.200800922, 19031432.
159. Wang J, Liu Y, Jiao F, Lao F, Li W, Gu Y, Li Y, Ge C, Zhou G, Li B, et al. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO2 nanoparticles. Toxicology 2008, 254(1-2):82-90. 10.1016/j.tox.2008.09.014, 18929619.
160. MacKay JA, Deen DF, Szoka FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Research 2005, 1035(2):139-153. 10.1016/j.brainres.2004.12.007, 15722054.
161. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the Brain: Approaches to Enhance Brain Drug Delivery. CNS Drugs 2009, 23:35-58. 10.2165/0023210-200923010-00003, 19062774.
162. Wang Y-C, Wu Y-T, Huang H-Y, Lin H-I, Lo L-W, Tzeng S-F, Yang C-S. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 2008, 29(34):4546-4553. 10.1016/j.biomaterials.2008.07.050, 18774604.
163. Chen X, Schluesener HJ. Nanosilver: A nanoproduct in medical application. Toxicology Letters 2008, 176(1):1-12. 10.1016/j.toxlet.2007.10.004, 18022772.
164. Tian F, Cui D, Schwarz H, Estrada G, Kobayashic H. Cytotoxicity of single-wall carbon nanotubes on human fibroblasts. Toxicology in vitro 2006, 20(7):1202-1212. 10.1016/j.tiv.2006.03.008, 16697548.
165. Beyerle A, Merkel O, Stoeger T, Kissel T. PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure-function relationships. Toxicol Appl Pharmacol 2010, 242(2):146-54. 10.1016/j.taap.2009.10.001, 19822165.
166. Borm P, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K, Schins R, Stone V, Kreyling W, Lademann J, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Particle and Fibre Toxicology 2006, 3(1):11. 10.1186/1743-8977-3-11, 1584248, 16907977.
167. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJAM. What do we (need to) know about the kinetic properties of nanoparticles in the body?. Regulatory Toxicology and Pharmacology 2007, 49(3):217-229. 10.1016/j.yrtph.2007.07.006, 17868963.
168. Kreyling WG, Möller W, Semmler-Behnke M, Oberdörster G. Particle dosimetry: deposition and clearance from the respiratory tract and translocation towards extrapulmonary sites. Particle Toxicology 2007, 47-74. CRC Press, Boca Raton, Donaldson K, Borm P.
169. Kreyling WG, Geiser M. Uptake and Distribution of Inhaled Nanoparticles. Nanoparticles in Medicine and Environment, Inhalation and Health Effects 2009, 138-176. Springer Berlin, Marijnissen JC, Gradon L.
170. Kreyling WG, Semmler-Behnke M, Moller W. Ultrafine Particle-Lung Interactions: Does Size Matter?. Journal of Aerosol Medicine 2006, 19(1):74-83. 10.1089/jam.2006.19.74, 16551218.
171. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113(7):823-839. 1257642, 16002369.
172. Wiebert P, Sanchez-Crespo A, Seitz J, Falk R, Philipson K, Kreyling WG, Moller W, Sommerer K, Larsson S, Svartengren M. Negligible clearance of ultrafine particles retained in healthy and affected human lungs. Eur Respir J 2006, 28(2):286-290. 10.1183/09031936.06.00103805, 16641121.
173. Stoeger T, Reinhard C, Takenaka S, Schroeppel A, Karg E, Ritter B, Heyder J, Schulz H. Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice. Environ Health Perspect 2006, 114(3):328-333. 1392224, 16507453.
174. Stoeger T, Takenaka S, Frankenberger B, Ritter B, Karg E, Maier K, Schulz H, Schmid O. Deducing In vivo Toxicity of Combustion-Derived Nanoparticles from a Cell-Free Oxidative Potency Assay and Metabolic Activation of Organic Compounds. Environ Health Perspect 2009, 117:54-60. 2627865, 19165387.
175. Peters A, Veronesi B, Calderón-Garcidueñas L, Gehr P, Chen LC, Geiser M, Reed W, Rothen-Rutishauser B, Schürch S, Schulz H. Translocation and potential neurological effects of fine and ultrafine particles a critical update. Particle and Fibre Toxicology 2006, 3:13-26. 10.1186/1743-8977-3-13, 1570474, 16961926.
176. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006, 311(5761):622-7. 10.1126/science.1114397, 16456071.
177. Brodeur G. Molecular Basis For Heterogeneity in Human Neuroblastomas. Eur J Cancer 1995, 31(A):505-510.
178. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006, 5(2):118-122. 10.1038/nmat1571, 16444262.
179. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix R, et al. Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme. Journal of Neuro-Oncology 2007, 81(1):53-60. 10.1007/s11060-006-9195-0, 16773216.
180. Alonzi R, Hoskin P. Functional Imaging in Clinical Oncology: Magnetic Resonance Imaging- and Computerised Tomography-based Techniques. Clinical Oncology 2006, 18(7):555-570. 10.1016/j.clon.2006.06.002, 16969988.
181. Leergaard TB, Bjaalie JG, Devor A, Wald LL, Dale AM. In vivo tracing of major rat brain pathways using manganese-enhanced magnetic resonance imaging and three-dimensional digital atlasing. NeuroImage 2003, 20(3):1591-1600. 10.1016/j.neuroimage.2003.07.009, 14642470.
182. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews 2008, 60(11):1252-1265. 10.1016/j.addr.2008.03.018, 2702670, 18558452.
183. Liu W, Frank JA. Detection and quantification of magnetically labeled cells by cellular MRI. European Journal of Radiology 2009, 70(2):256-264.
184. Suci PA, Berglund DL, Liepold L, Brumfield S, Pitts B, Davison W, Oltrogge L, Hoyt KO, Codd S, Stewart PS, et al. High-Density Targeting of a Viral Multifunctional Nanoplatform to a Pathogenic, Biofilm-Forming Bacterium. Chemistry & Biology 2007, 14(4):387-398.
185. Fiandaca MS, Varenika V, Eberling J, McKnight T, Bringas J, Pivirotto P, Beyer J, Hadaczek P, Bowers W, Park J, et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. NeuroImage 2009, 47(Suppl 2):T27-T35. 10.1016/j.neuroimage.2008.11.012, 2730220, 19095069.
186. Urakami T, Kawaguchi AT, Akai S, Hatanaka K, Koide H, Shimizu K, Asai T, Fukumoto D, Harada N, Tsukada H, Oku N. In vivo Distribution of Liposome-Encapsulated Hemoglobin Determined by Positron Emission Tomography. Artificial Organs 2009, 33(2):164-168. 10.1111/j.1525-1594.2008.00702.x, 19178462.
187. Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P. 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. International Journal of Hyperthermia 2006, 22(4):319-325. 10.1080/02656730600734128, 16754352.
188. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotech 2005, 23(3):313-320.
189. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R. Novel receptor-targeted fluorescent contrast agents for in vivo tumour imaging. Invest Radiol 2000, 35(8):479-485. 10.1097/00004424-200008000-00004, 10946975.
190. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumours based on a receptor-targeted dye-peptide conjugate platform. Journal of Biomedical Optics 2001, 6(2):122-133. 10.1117/1.1352748, 11375721.
191. Weissleder R, Tung C-H, Mahmood U, Bogdanov A. In vivo imaging of tumours with protease-activated near-infrared fluorescent probes. Nat Biotech 1999, 17(4):375-378.
192. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008, 452(7187):580-589. 10.1038/nature06917, 2708079, 18385732.
193. Ntziachristos V, Yodh AG, Schnall MD, Chance B. MRI-Guided Diffuse Optical Spectroscopy of Malignant and Benign Breast Lesions. Neoplasia 2002, 4(4):347-354. 10.1038/sj.neo.7900244, 1661680, 12082551.
194. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, Jacks T, Weissleder R. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci 2005, 102(40):14404-14409. 10.1073/pnas.0503920102, 1242291, 16183744.
195. Ntziachristos V, Tung C-H, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nature Med 2002, 8:757-760. 10.1038/nm729, 12091907.
196. Sosnovik DE, Nahrendorf M, Deliolanis N, Novikov M, Aikawa E, Josephson L, Rosenzweig A, Weissleder R, Ntziachristos V. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007, 115:1384-1391. 10.1161/CIRCULATIONAHA.106.663351, 17339546.
197. Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A, Josephson L, Weissleder R. Visualization of antitumour treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(33):12294-12299. 10.1073/pnas.0401137101, 514472, 15304657.
198. Corlu A, Choe R, Durduran T, Rosen MA, Schweiger M, Arridge SR, Schnall MD, Yodh AG. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express 2007, 15(11):6696-6716. 10.1364/OE.15.006696, 19546980.
199. Graves E, Ripoll J, Weissleder R, Ntziachristos V. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys 2003, 30(5):901-911. 10.1118/1.1568977, 12772999.
200. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003, 9(1):123-128. 10.1038/nm0103-123, 12514725.
201. Ntziachristos V, Leroy-Willig A, Tavitian B, . (Editors) Textbook of in vivo Imaging in Vertebrates 2007, Wiley, NY, (Editors).
202. Helmchen F, Denk W. Deep tissue two-photon microscopy. Nature Methods 2005, 2:932-940. 10.1038/nmeth818, 16299478.
203. Huisken J, et al. Optical sectioning deep inside live embryos by selective plane illumination microscopy. Science 2004, 305:1007. 10.1126/science.1100035, 15310904.
204. Benaron DA, Hintz SR, Villringer A, Boas D, Kleinschmidt A, Frahm J, Hirth C, Obrig H, Van Houten JC, Kermit EL, Cheong W, Stevenson DK. Noninvasive functional imaging of human brain using light. J Cerebral Blood Flow and Metabolism 2000, 20:469-477.
205. Ntziachristos V, Weissleder R. Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett 2001, 26(12):893-895. 10.1364/OL.26.000893, 18040483.
206. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003, 13(1):195-208.
207. Deliolanis, et al. Free-space fluorescence molecular tomography utilizing 360 geometry projections. Optics Letters 2007, 32(4):382-384. 10.1364/OL.32.000382, 17356660.
208. Hyde D, de Kleine R, MacLaurin SA, Miller E, Brooks DH, Krucker T, Ntziachristos V. Hybrid FMT-CT imaging of amyloid-[beta] plaques in a murine Alzheimer's disease model. NeuroImage 2009, 44(4):1304-1311. 10.1016/j.neuroimage.2008.10.038, 19041402.
209. McCann CM, Waterman P, Figueiredo J-L, Aikawa E, Weissleder R, Chen JW. Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. NeuroImage 2009, 45(2):360-369. 10.1016/j.neuroimage.2008.12.022, 2707831, 19154791.
210. Vinegoni C, Pitsouli C, Razansky D, Perrimon N, Ntziachristos V. In vivo imaging of Drosophila melanogaster pupae with mesoscopic fluorescence tomography. Nat Meth 2008, 5(1):45-47.
211. Razansky D, Ntziachristos V. Hybrid photoacoustic fluorescence molecular tomography using finite-element-based inversion. Med Phys 2007, 34:4293-4301. 10.1118/1.2786866, 18072494.
212. Wang X, Pang Y, Ku G, Xie X, Stoica G, Wang LV. Noninvasive laserinducedphotoacoustic tomography for structural and functional imaging of the brain. Nature Biotechnology 2003, 21:803-806. 10.1038/nbt839, 12808463.
213. Zhang HF, Maslov K, Stoica G, Wang V. Functional photoacoustic microscopy for high-resolution and noninvasive imaging. Nature Biotechnology 2006, 24:24848-851.
214. Niederhauser JJ, Jaeger M, Lemor R, Weber P, Frenz M. Combined ultrasound and optoacoustic system for real-time high-contrast vascular imaging in vivo. IEEE Trans Med Imag 2005, 24:436-440.
215. Hu H, Maslov K, Wang LV. Noninvasive label-free imaging of microhemodynamics by optical-resolution photoacoustic microscopy. Opt Express 2009, 17:7688-7693. 10.1364/OE.17.007688, 2711847, 19399148.
216. Razansky D, Vinegoni C, Ntziachristos V. Imaging of mesoscopic-scale organisms using selective-plane optoacoustic tomography. Physics in medicine and biology 2009, 54(9):2769-2777. 10.1088/0031-9155/54/9/012, 19369709.
217. Ma R, Taruttis A, Ntziachristos V, Razansky D. Multispectral optoacoustic tomography (MSOT) scanner for whole-body molecular imaging. Optics Express 2009, 17(24):21414. 10.1364/OE.17.021414, 19997381.
218. Yang X, Wang L. Monkey brain cortex imaging by photoacoustic tomography. J Biomed Opt 2008, 13(4):044009. 10.1117/1.2967907, 19021337.
219. Manohar S, Vaartjes SE, van Hespen JCG, Klaase JM, Engh FM, Steenbergen W, van Leeuwen TG. Initial results of in vivo non-invasive cancer imaging in the human breast using near-infrared photoacoustics. Opt Express 2007, 15:12277-12285. 10.1364/OE.15.012277, 19547596.
220. Ungureanu C, Van Weperen T, Sijl J, Rayavarapu R, Manohar S, Versluis M, Van Leeuwen TG. Acoustic signals from gold nanoparticles irradiated with pulsed lasers. The Journal of the Acoustical Society of America 2008, 123(5):3370.
221. de la Zerda A, Zavaleta C, Keren S, Vaithilingam S, Bodapati S, Liu Z, Levi J, Ma T-J, Oralkan O, Cheng Z, Chen X, Dai H, Khuri-Yakub BT, Gambhir SS. Photoacoustic Molecular Imaging in Living Mice Utilizing Targeted Carbon Nanotubes. Nature Nanotech 2008, 3:557-562.
222. Razansky D, Vinegoni C, Ntziachristos V. Multispectral photoacoustic imaging of fluorochromes in small animals. Optics Letters 2007, 32:289-293. 10.1364/OL.32.002891, 17215948.
223. Razansky D, Baeten J, Ntziachristos V. Sensitivity of molecular target detection by multispectral optoacoustic tomography (MSOT). Medical physics 2009, 36(3):939-945. 10.1118/1.3077120, 19378754.
224. Jagger C, Gillies C, Moscone F, Cambois E, Van Oyen H, Nusselder W, Robine JM. Inequalities in healthy life years in the 25 countries of the European Union in 2005: a cross-national meta-regression analysis. Lancet 2008, 372(9656):2124-2131. 10.1016/S0140-6736(08)61594-9, 19010526.
225. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008, 4(4):273-82.
226. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008, 17(2):89-101. 10.1159/000112961, 18287791.
227. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26(1):57-64.
228. Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC, Sung HW. Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 2006, 27(9):2051-2059. 10.1016/j.biomaterials.2005.10.027, 16307794.
229. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 2009, 15(17):5569-75. 10.1158/1078-0432.CCR-09-0522, 19706807.
230. Nanotechnology inClinical Trials. National Cancer Institute'sAlliance for Nanotechnology in Cancer. , http://nano.cancer.gov/learn/now/clinical-trials.asp